United States: No Causation, No Claim

Last Updated: January 6 2014
Article by Steven Boranian

Today we feature a case that exemplifies two principles that we routinely encounter in our practices, but rarely at the same time. First, there is no more sympathetic plaintiff than a disabled military veteran. We come across and write on cases involving sad facts with some regularity, which is an occupational hazard of our practice in the drug and medical device arena. The most compelling cases we see involve patients who have experienced actual injuries, a fact that we always bear in mind as we report on what the law is and what we believe the law should be. Moreover, while everyone has a point of view on what kinds of cases provoke the greatest sympathy, we have learned in our many years on Reed Smith's Pro Bono Committee that disabled veterans garner the broadest imaginable support. Some people champion children's issues; others promote immigration reform, or perhaps they favor housing rights. But everyone gets behind programs supporting disabled veterans. And rightfully so. Today's veterans are young men and women who have completed their service and have their whole lives ahead of them, often with significant challenges.

The second principle that today's case brings to mind is that civil litigation cannot and should not provide a remedy if the law and facts are not there to support one, no matter how sympathetic the plaintiff may be. The district court's order granting summary judgment in Carnes v. Eli Lilly& Co., No. 0:13-591-CMC, 2013 U.S. Dist. LEXIS 176201 (D.S.C. Dec. 16, 2013), brings together these two principles by presenting a disabled Army veteran and physicians who prescribed prescription drugs with full knowledge of all the relevant risks. In Carnes, the plaintiff injured his spinal cord while attempting to rescue fellow soldiers in Iraq, and as a result he is wheelchair bound, has significant physical limitations, and suffers from chronic pain. Id. at *1. One physician prescribed Lyrica, an antiepileptic drug indicated for treating pain associated with spinal cord injury, but after about three years on the drug, the plaintiff asked to stop. Id. at *2. The doctor therefore prescribed Cymbalta, which is a serotonin and norepinephrine reuptake inhibitor that is also indicated for treatment of chronic pain. After a few months, the plaintiff changed doctors and asked to switch his medication again because he thought the drug was causing him to gain weight. Id. at *2. The new doctor therefore tapered the plaintiff off Cymbalta and restarted Lyrica. Id. at **2-3. According to the doctor, she tapered the plaintiff's dose "to avoid potential side effects from stopping Cymbalta suddenly." Id. at *3.

As the second doctor's remarks suggest, discontinuing Cymbalta can result in withdrawal-like symptoms, which the doctor knew about and which the product's label disclosed at all relevant times. Id. at **4-5. The physician who first prescribed the drug similarly was aware of the risk of withdrawal symptoms "having learned about them in medical school, during his residency, and from patients who experienced withdrawal symptoms." Id. at *16. Alas, the plaintiff experienced post-discontinuation symptoms that he attributed to the drug, including sharp headaches, nightmares, anger, and shaking. He therefore sued the drug's manufacturer, who moved for summary judgment under South Carolina's learned intermediary doctrine.

The district court's order granting summary judgment is useful on multiple levels. To start, the court observed that "[p]rescription drugs are neither defective nor unreasonably dangerous if accompanied by proper direction and warnings," which reiterates to us that South Carolina applies comment k across the board to all prescription drug cases. Id. at *9. In addition, the court confirmed that South Carolina applies the learned intermediary doctrine in prescription drug cases and that "a plaintiff must not only show that the drug manufacturer's warning was inadequate, but 'also that the inadequacy of the warning was the proximate cause of the plaintiff's injury.'" Id. at *10. Lots of courts have made statements like this under various states' laws, and our readers will find the statement a familiar truth. This court, however, went a helpful step further and explained exactly what warnings causation means, i.e., that different or additional information would have changed the physician's prescribing decision. As the court put it,

In light of the learned intermediary doctrine, 'the burden remains on the plaintiff to demonstrate that the additional non-disclosed risk was sufficiently high that it would have changed the treating physician's decision to prescribe the product for the plaintiff.'"

Id at *10. This is not an extraordinary holding, but it is reassuring to see a court lay out the rule so clearly and completely. We have often said that warnings causation is a powerful element because it forecloses liability for failure to warn in the abstract. Maybe the labeling could reasonably have been stronger or more complete in some conceivable way. Or maybe it could not have. We have no reason to believe that the warnings at issue in Carnes were in any way less than adequate, but either way, we do know that the court asked the correct question: Would additional warnings have made any difference for this actual plaintiff vis-à-vis his physician's decision to prescribe the drug?

This court clearly understood the law and properly placed the burden on the plaintiff. With regard to the doctor who initially prescribed the drug, the plaintiff argued that certain study results should have been disclosed in the label, but the doctor "testified that had he been provided the warning Plaintiffs allege would have been adequate, he still would have prescribed." Id. at *14. There is no more clear break in the causal chain than this, particularly where the plaintiff has set forth specific information that the alternate "adequate" label allegedly should have included. We think every plaintiff claiming inadequate warnings should have to set forth a proposed alternative, but many get away with leveling only vague criticisms.

Nor was the plaintiff able to salvage his warnings-based claims by taking the doctor out of the equation. The plaintiff argued that he as a patient would not have taken the drug if he personally had known about the risk of withdrawal, thus attempting "[w]ithout any legal authority . . . to displace the learned intermediary doctrine." Id. at *14. But the court correctly ruled that the law "requires the court to focus on the physician's decision to prescribe the drug." Id. at *15 (emphasis added). With regard to the doctor who tapered the plaintiff off Cymbalta, she too testified that even if the label had included information that the plaintiff said should have been there, she still would have gradually reduced his dose, just as she did when she made her actual treating decisions. Id. at *21. Case closed.

The court's disciplined order is all the more admirable because it was filed nine days before Christmas, a time of year when the sympathy toward a disabled war hero might have been heightened. However, in light of the evidence as the court described it, this is the correct result based on correct reasoning, and the court's very clear restatement and application of the learned intermediary doctrine is a good example to file away for future use.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Reed Smith
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Reed Smith
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions